| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 206.7 | 224.5 |
| Gross profit | 177.9 | 192.7 |
| Profit before tax | -25.0 | 13.6 |
| Net income | -24.4 | 9.9 |
| EPS (diluted, $ a share) | $-0.84 | $0.34 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -7.9% |
|---|---|
| Gross margin | 86.0% |
| Operating margin | -13.9% |
10-Q filed with the SEC, NYSE: INSP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Inspire Medical Systems, Inc.: key numbers
- Share price
- $59.12Close, Nov 16
- Market cap
- $1.71B
- Shares outstanding
- 28.97MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Inspire Medical Systems, Inc.
All →Inspire Medical Systems Earnings Call: Key Takeaways
Inspire Medical reported a 7.9% year-over-year revenue decline due to $120 million in coding headwinds, while focusing on a 2027 return to growth.
- Call
- Nov 2, 2026, 5:00 PM ET
Inspire Medical Systems Financial Results
Inspire Medical Systems reported Q3 2026 revenue of $206.7 million, a 7.9% decrease year-over-year primarily due to U.S. coding and reimbursement challenges. Despite the revenue decline, the company achieved a positive adjusted diluted EPS of $0.14 and noted that the AMA approved new Category I CPT codes for its Inspire V system effective 2028.
- Term
- 3 months
“We are pleased to have delivered sequential growth in the third quarter, with U.S. performance coming in ahead of our expectations. Results suggest that, despite some lingering headwinds, there is greater comfort among implanting physicians with the current coding dynamic.”
Tim Herbert, Chairman and CEO of Inspire Medical Systems
“Looking further ahead, we were also pleased with the AMA Editorial Panel’s September approval of a new CPT® code for single lead HGNS devices, including the Inspire V system. When this takes effect in January 2028, a dedicated code set will give physicians and hospitals enhanced clarity around coding and reimbursement and, in turn, further enable patient access to Inspire therapy.”
Tim Herbert, Chairman and CEO of Inspire Medical Systems